Supplemental New Drug Application For BYETTA Submitted To FDA For Use With TZDs (Medical News Today)
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) announced the recent submission of a supplemental New Drug Application to the Food and Drug Administration (FDA) to seek approval for expanded use of BYETTA (exenatide) injection as add-on therapy to a common class of oral diabetes medication called thiazolidinediones (or TZDs), in people with type 2 diabetes who